C10931: Markers for Diagnosis and/or Prognosis of Irritable Bowel Disease and Syndrome
Value Proposition: - The identified markers may be combined to optimize sensitivity and specificity. - These markers may be used in ELISA or Chip format. - Markers have been validated using colonic tissue biopsy samples. - Predicate technology and CPT codes already exist. - This technology is predicted to be priced lower than current tests which will likely allow faster acceptance by doctors and patients. - A diagnostic test may be developed to detect these markers in patient blood, serum, plasma or tissue.
Technical Details:
Inventors have identified certain cytokines as markers to diagnose Irritable Bowel Disease (IBD) and Irritable Bowel Syndrome (IBS). These markers may also be used to detect therapy response in these conditions and can differentiate between IBD, IBS, ulcerative colitis and crohn’s disease.
Looking for Partners:
This technology may be further developed to diagnose and/or evaluate IBD or IBS and also to assess therapy response in these conditions.
Publications/Associated Cases:
Associated Case: C11385
